Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes
Abstract
LIGHT, a ligand for lymphotoxin‐β receptor (LTβR) and herpes virus entry mediator, is predominantly expressed on activated immune cells and LTβR signaling leads to the recruitment of lymphocytes. The interaction between LIGHT and LTβR has been previously shown to activate immune cells and result in tumor regression in a virally‐induced tumor model, but the role of LIGHT in tumor immunosuppression or in a prostate cancer setting, where self antigens exist, has not been explored. We hypothesized that forced expression of LIGHT in prostate tumors would shift the pattern of immune cell infiltration toward an anti‐tumoral milieu, would inhibit T regulatory cells (Tregs) and would induce prostate cancer tumor associated antigen (TAA) specific T cells that would eradicate tumors.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 14, 2014
- Source ID
- 10.1002/pros.22914
Entities
People
- Andrew Gray
- Bhavna Verma
- Diane M. Da Silva
- Heike E. Brand
- Joseph G. Skeate
- Lisa Yan
- Shreya Kanodia
- Tania B. Porras
- W. Martin Kast
Organizations
- Cedars-Sinai Medical Center
- National Institutes of Health
- United States Department of Defense
- University of Southern California